Engineered blood stem cells become lifetime antibody factories against HIV, malaria and flu
What if your immune system could be programmed once and then protect you for life, without ever needing a booster? Researchers have now made that idea work in blood stem cells, and the implications stretch well beyond infectious disease.
The immune system is powerful but impermanent. After a vaccine or infection, B cells ramp up antibody production, but that output typically fades over time. For most diseases, that is manageable, immune memory kicks back in when needed. But for illnesses like HIV and malaria, against which no existing vaccine works reliably, that fading response is a fundamental failure. The viruses evolve faster than the immune system can keep up.
A team of researchers has now taken a different route. Rather than training the immune system through vaccination, they genetically engineered the blood stem cells themselves, the precursor cells that give rise to all blood cells, including B cells. Those modified stem cells were programmed to continuously produce B cells that churn out a specific, broadly acting antibody. Not temporarily, but for life. The research was reported by Lifespan.io, based on findings around this engineered stem cell platform.
Why ordinary vaccines fall short here
The antibodies at the center of this work are rare. Known as broadly neutralizing antibodies, they do not target one specific variant of a virus but instead attack a conserved, stable region shared across many strains. For HIV, which mutates rapidly, this approach sidesteps the problem of viral escape. The trouble is that the human immune system almost never produces these antibodies naturally, and vaccines have so far failed to reliably induce them.
By embedding the genetic instructions for such an antibody directly into stem cells, researchers bypass the vaccination problem entirely. The cell knows from the outset what to make, regardless of how the virus evolves. In theory, a person receives one treatment, a form of one-time cell therapy, and the body defends itself for the rest of their life.
A platform, not just a treatment
The researchers emphasize that the platform is not limited to infectious disease. The same technique could, in principle, be used to produce other proteins on a lifelong basis, enzymes missing in genetic disorders, or proteins involved in slowing aging processes. That makes the approach relevant to longevity science more broadly.
Significant hurdles remain. The long-term safety of genetically modified stem cells is not yet fully established. There are theoretical risks of uncontrolled cell growth or immune reactions against the modified cells. And the question of how such a therapy could become affordable and accessible to the billions of people most vulnerable to HIV and malaria, predominantly in low- and middle-income countries, remains entirely unanswered.